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Abstract
Background: Active dendritic cell (DC) immunization protocols are rapidly gaining interest as therapeutic options
in patients with acute myeloid leukemia (AML). Here we present for the first time a GMP-compliant 3-day protocol
for generation of monocyte-derived DCs using different synthetic Toll-like receptor (TLR) agonists in intensively
pretreated patients with AML.
Methods: Four different maturation cocktails were compared for their impact on cell recovery, phenotype,
cytokine secretion, migration, and lymphocyte activation in 20 AML patients and 25 healthy controls.
Results: Maturation cocktails containing the TLR7/8 agonists R848 or CL075, with and without the addition of the
TLR3 agonist poly(I:C), induced DCs that had a positive costimulatory profile, secreted high levels of IL-12(p70),
showed chemotaxis to CCR7 ligands, had the ability to activate NK cells, and efficiently stimulated antigen-specific
CD8
+ T cells.
Conclusions: Our results demonstrate that this approach translates into biologically improved DCs, not only in
healthy controls but also in AML patients. This data supports the clinical application of TLR-matured DCs in patients
with AML for activation of innate and adaptive immune responses.
Background
Acute myeloid leukemia (AML) is the most common acute
leukemia in adults, with a poor prognosis and an overall
survival (OS) rate of only 23.6% at 5 years (SEER data).
Current risk-adapted treatment approaches are determined
by several parameters, including cytogenetic characteristics
of AML, molecular genetics, age, initial blast count, early
blast clearance, and performance status. Although com-
plete remission (CR) rates are high, the majority of patients
will suffer from relapse. In the last three decades, various
post-remission strategies for elimination of minimal resi-
dual disease (MRD) have been developed. The optimal
consolidation therapy has not been identified, and patients
are offered cytarabine-containing regimens, allogeneic or
autologous hematopoietic stem cell transplantation
(HSCT), maintenance therapy, and more recently IL-2 in
combination with histamine dihydrochloride according to
individual risk profile and accompanying morbidity [1,2].
Allogeneic HSCT was shown to provide a potent immuno-
logical anti-leukemic effect, with the lowest rate of relapse
and a relevant benefit for overall survival in certain age
groups [3]. However, this approach is restricted to a subset
of patients due to patient-associated morbidity and mortal-
ity, donor availability, recipient comorbidities, or age. Clini-
cal vaccination trials with peptides derived from leukemia-
associated antigens like proteinase 3 (PR1), Wilm’s tumor
gene product 1 (WT-1), and the receptor for hyaluronic
acid-mediated motility (RHAMM or CD168) have tried to
stimulate autologous anti-leukemic T cell responses and
have shown promising results regarding immunogenicity
and clinical efficacy [4-8].
More recently, an active immunization study with
WT-1 RNA-transfected autologous DCs showed immu-
nogenic and anti-leukemic activity while overcoming the
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DCs are recognized as key regulators of the human
immune system, with the ability to induce and maintain
primary immune responses as well as tolerance in vitro
and in vivo [10,11]. They have been tested as cellular
adjuvants for therapeutic vaccination of solid and hema-
tological malignancies in more than 100 clinical trials
since 1996 and proven feasibility and safety. Although
immune responses, such as induction of tumor-specific
T cells, were observed in many studies, overall clinical
response rates remain low. The vast majority of DCs
used for clinical trials were derived from autologous
peripheral blood monocytes and differentiated with a
standard maturation cocktail composed of the cytokines
TNF-a,I L - 1 b,I L - 6 ,a n dP G E 2, therefore they lack the
capacity to secrete biologically active IL-12(p70) [12].
For optimal T cell activation, it is required that DCs dis-
play peptides within MHC molecules as signal 1 and
costimulatory molecules as signal 2. In addition, produc-
tion of IL-12(p70) as signal 3 is desired because of its
leading role in promoting T helper 1 (TH1) cell polariza-
tion and supporting the development of CD8
+ cytotoxic
T lymphocytes, thereby fostering the appropriate adap-
tive immune responses needed to combat minimal resi-
dual disease and control outgrowth of malignant cells in
tumor patients [13,14]. Recently, cocktails containing
synthetic TLR agonists emerged as an attractive alterna-
tive for the induction of DC maturation [15-18]. TLRs
recognize pathogen-derived signals, and stimulation
leads to an induction of a TH1 immune response via
IL-12(p70). Several synthetic TLR agonists could be
identified so far. R848 is a low molecular weight syn-
thetic imidazoquinoline compound which activates
immune cells via the TLR7/TLR8 MyD88-dependent
signaling pathway [17]. Recently, R848 was shown to
trigger NF-B activation in cells expressing murine
TLR8 when combined with poly(dT) [19]. CL075 (3M-
002) is a thiazoloquinolone derivative that stimulates
TLR8 in human peripheral blood mononuclear cells
(PBMCs) [20]. It also activates NF-B and preferentially
triggers the production of TNF-a and IL-12(p70). Polyi-
nosine-polycytidylic acid (poly(I:C)) is a synthetic analog
of double-stranded RNA (dsRNA), a molecular pattern
associated with viral infection. It is composed of a
strand of poly(I) annealed to a strand of poly(C) [21].
Poly(I:C) is recognized by TLR3 located mostly in endo-
somal membranes. It leads to induction of inflammation
and long-lasting T cell immunity and matures both
mouse and human DCs in a type I IFN dependent fash-
ion [22-24]. The rational for the choice of TLR-agonists
was not only based on in vitro evidence of effective DC
activation but also upon consideration of GMP availabil-
ity for usage in a clinical trial.
Our present investigation was designed to study the
feasibility of a clinical grade 3-day DC generation protocol
from non-leukemic monocytes of intensively pretreated
AML patients. Novel cocktails containing different syn-
thetic TLR-agonists were used for maturation and were
analyzed for their phenotype, costimulatory profile, cyto-
kine secretion pattern, migratory capacity and functional
capacity to stimulate NK and T cells.
We were able to show that phenotypically and function-
ally mature DCs can be generated from heavily pretreated
patients with AML as compared to healthy controls. The
four different cocktails did not translate into significant
differences in the patient and donor cohort. We conclude
that this approach is feasible and supports the clinical
application of autologous DCs after TLR-maturation in
patients with AML for the induction of potent innate and
adaptive immune responses.
Methods
Source of primary cells
After written informed consent in accordance with the
Declaration of Helsinki and approval by the Institutional
Review Board of the Ludwig-Maximilians-University
(Munich, Germany), peripheral blood samples were
obtained from 20 patients with AML in complete remis-
sion before initiation of consolidation or maintenance
therapy or continuation of the latter. Several patients
donated peripheral blood repeatedly. As control group, 25
healthy donors were recruited. The clinical characteristics
of the patients are summarized in Table 1.
Cell isolation and generation of mature DCs from PBMCs
In brief, PBMCs were isolated by Ficoll/Hypaque (Bio-
chrom, Berlin, Germany) density gradient centrifugation.
Cells were resuspended in RPMI 1640 medium with very
low endotoxin (Biochrom, Berlin, Germany), supplemen-
ted with 1.5% human serum (pool of AB-positive adult
males) (Institute of Transfusion Medicine, Suhl, Germany)
- hereafter named DC medium - and allowed to adhere in
6-well plates (Becton Dickinson, Franklin Lakes, NJ, USA)
at a concentration of 5 × 10
6 cells/mL and a final volume
of 2 mL. Non-adherent cells were removed after 90 min of
incubation at 37°C and 5% CO2.
Immature DCs were generated by culturing the adherent
mononuclear cells in medium supplemented with human
recombinant GM-CSF (800 IU/mL, Leukine
®, Bayer,
Leverkusen, Germany) and human recombinant IL-4 (580
IU/mL, R&D Systems, Wiesbaden, Germany). After 48 h
DCs were additionally cultured with TNF-a at 1100 IU/
mL, IL1-b at 2000 IU/mL (R&D Systems), IFN-g at 5000
IU/mL (Imukin
®, Boehringer Ingelheim, Ingelheim, Ger-
many), PGE2 at 250 ng/mL (Prostin
® E2, Pfizer, Borgo San
Michele, Italy), and, according to the defined cocktail,
R848 at 1 μg/mL or CL075 at 1 μg/mL with or without
Beck et al. Journal of Translational Medicine 2011, 9:151
http://www.translational-medicine.com/content/9/1/151
Page 2 of 14poly(I:C) at 20 ng/mL (all InvivoGen, San Diego, CA,
USA) for 24 hours. The different 3-day DC generation
cocktails are summarized in Table 2.
Antibodies and multimers
For surface phenotyping, cells were labeled with the fol-
lowing fluorescence-conjugated monoclonal antibodies:
CD1a (FITC, clone F7141, Dako Cytomation, Glostrup,
Denmark), CD3 (FITC, clone UCHT1, eBiosciences, San
Diego, CA, USA), CD4 (APC, clone RPA-T4, BD Bios-
ciences (BD), Heidelberg, Germany), CD8 (FITC, clone
HIT8a, BD), CD14 (FITC, clone 61D3, eBiosciences),
CD19 (PE, clone HIB19 eBiosciences), CD40 (PE, clone
5C3, eBiosciences), CD56 (PE, clone B159, BD), CD69
(APC, clone FN50, Miltenyi Biotec, Bergisch Gladbach,
G e r m a n y ) ,C D 8 0( P E ,c l o n eL 3 0 7 . 4 ,B D ) ,C D 8 3( P E ,
clone HB15e, eBiosciences), CD86 (FITC, clone 2331
(FUN-1), BD), CD209 (FITC, clone DCN46, BD), CD273
(APC, clone MIH18, BD), CD274 (FITC, clone MIH1,
BD), CCR7 (APC, clone FR11-11E8, Miltenyi Biotec),
HLA-DR (PE, clone L203, R&D Systems), and corre-
sponding mouse IgG isotype controls were used (FITC,
PE and APC, eBiosciences). The percentage of positive
cells was determined by subtracting the percentage of
cells stained positive with the isotype-matched antibody
(set at or below 1%) from the percentage of cells posi-
tively stained with the specific antibody. The relative
mean fluorescence intensity (MFI) was calculated by
dividing the MFI of the measured population by the MFI
of cells stained with the isotype-matched antibody. The
values are shown as mean ± standard deviation. Multi-
mers were synthesized as previously reported [25]. Speci-
fic multimers were used for the peptides A2-CMVpp65
and A2-WT-1 as well as control multimer detecting A2-
HIV-gag (kindly provided by D. Busch, Technical Univer-
sity Munich, Munich, Germany). After washing and fixa-
tion in FACS buffer containing 2% formaldehyde, the
cells were analyzed by flow cytometry using a FACS
Table 1 Patient characteristics
Patient Gender Age
(years)
FAB Karyotype Molecular mutations
FLT3-ITD MLL-PTD NPM1
# 1 M 64 M2 46, XY - - +
# 2 M 71 M4 46, XY + - +
# 3 M 45 M3v 46, XY, t(15;17) - - -
# 4 F 70 M1 46, XX - - -
# 5 M 69 M4 46, XY - - +
# 6 F 23 M2 46, XX + - +
# 7 M 36 M3 46, XY, t(15;17) - - -
# 8 F 34 M3 46, XX, t(15;17) - - -
# 9 M 51 M3 46, XY, t(15;17) - - -
# 10 F 39 M2 46, XX - - -
# 11 M 48 M2 46, XY - - -
# 12 M 62 M4 46, XY +
(1) -+
# 13 M 37 M3v 46, XY, t(15;17) + - -
# 14 M 63 M4 46, XY - - -
# 15 M 72 M2 45, X, (-Y) + - +
# 16 F 70 M2 46, XX, t(8;21) - - -
# 17 F 32 M5a 46, XX - - -
# 18 M 55 M4 46, XY + - +
# 19 M 67 M0 51, XY, +9, +10, +11, +13 × 2, +3, - - -
# 20 F 28 sAML 46, XY - - +
Abbreviations: M, male; F, female; FAB, French-American-British classification system.
(1) AML #12 = FLT3-TKD mutation.
Table 2 Cocktails for DC maturation
Cocktail Inflammatory Cytokines/IFN Other
Additives
TLR Ligands
C TNF-a, IL-1b, IFN-g PGE2 CL075
CP TNF-a, IL-1b, IFN-g PGE2 CL075, poly(I:C)
R TNF-a, IL-1b, IFN-g PGE2 R848
RP TNF-a, IL-1b, IFN-g PGE2 R848, poly(I:C)
Following concentrations were used in the individual maturation cocktails:
All cocktails contained 1100 IU/mL TNF-a, 2000 IU/mL IL-1b, 5000 U/ml IFN-g
and 250 ng/ml PGE2.
Additional additives as follows:
Cocktail C: 1 μg/ml CL075
Cocktail CP: 1 μg/ml CL075 and 20 ng/ml poly (I:C)
Cocktail R: 1 μg/ml R848
Cocktail RP: 1 μg/ml R848 and 20 ng/ml poly (I:C)
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using FlowJo 8 software (Tree Star, Ashland, OR, USA).
Stability of DC phenotype (wash-out test)
Mature 3-day DCs were harvested and washed 2× with
DC medium to completely remove the maturation cock-
tail. Afterwards, DCs were re-plated in 96 well round
bottom wells in DC medium for 24 h. The cells were har-
vested and stained with the antibodies for various DC
surface markers and analyzed by flow cytometry.
Signal 3 assay of cytokine secretion
Mature DCs were cocultured with CD40L-expressing
L929 cells (CD40L transfected mouse fibroblasts, kindly
provided by A. Moosmann, Helmholtz Zentrum
München, Munich, Germany) as a model system for inter-
action with activated T cells. Briefly, 5 × 10
4 cells/well
CD40L-expressing L929 cells were irradiated (180 Gy,
cesium source), seeded in a 96-well plate, and allowed to
adhere for 24 h at 37°C and 5% CO2 in a humified atmo-
sphere. After coculture with 2 × 10
4 DCs for 24 h, super-
natant was harvested and analyzed by ELISA for the
concentration of IL-12(p70) and IL-10 according to the
manufacturer’s instructions (R&D Systems). Correspond-
ingly, DCs were also cocultured for 24h with allogeneic
and autologous non-adherent PBMCs and the supernatant
analyzed for IL-12(p70) and IL-10. Non-adherent PBMCs
and DCs alone served as a negative control. As applicable,
IL-2 (500 IU/mL, Proleukin
®, Novartis Pharma, Emery-
ville, CA) or phorbol 12-myristate 13-acetate (PMA,
20 ng/mL, Sigma-Aldrich, Deisenhofen, Germany) or
ionomycin (75 ng/mL, Sigma) was used as a positive
control.
Migration assay
After harvesting and washing, DCs were analyzed in a
transwell-migration assay. In brief, the lower culture
chamber of a 96-trans-well plate (Costar, Corning, USA)
was filled with 150 μL migration medium, consisting of
VLE-RPMI, 500 IU/mL GM-CSF, 250 IU/mL IL-4 and 1%
human serum, with or without the chemokine CCL19
(100 ng/mL, R&D Systems). DCs were seeded in the
upper chamber (5 × 10
4 cells/well) and incubated for 2 h
at 37°C and 5% CO2 in a humified atmosphere. DCs from
the upper and the lower chamber were collected separately
and counted using a Neubauer hemocytometer. Alterna-
tively, the cell number was determined by incubation with
CellTiter-Glo reagent according to the manufactor’s
instruction (Promega) and measured with the lumin-
ometer (Victor 3, Perkin Elmer).
NK cell activation
NK cells were isolated from fresh PBMCs of healthy
controls (HCs) by negative selection, according to the
manufacturer’s instructions (NK cell isolation kit, Milte-
nyi Biotech). Allogeneic NK cells were stimulated in a
10:1 ratio with DCs by coculture for 24 h in VLE-RPMI
supplemented with 10% human serum. As positive con-
trol, NK cells were stimulated with IL-2 (500 IU/mL).
After 24 h, the supernatant was collected and analyzed
for IFN-g concentration by ELISA (BD Biosciences). For
detection of activated NK cell populations, the cocul-
tured cells were stained with CD3, CD56, and CD69
and analyzed by flow cytometry.
NK cell activation in autologous and allogeneic setting
Non-adherent PBMCs from the same (autologous setup)
and an allogeneic donor were cocultured with mature DCs
at a ratio of 10:1 with and without the addition of IL-2
(500 IU/mL). As controls, PBMCs alone, PBMCs with
IL-2 (500 IU/mL) and PBMCs with PMA (20 ng/mL) and
ionomycin (75 ng/mL) were used. After incubation for
19 h, Golgi stop solution consisting of brefeldin A (10 μg/
mL, Sigma) and monensin (25 μM, Sigma) was added and
allowed to incubate for additional 5 h. The cells were har-
vested after a total incubation time of 24 h and stained
with the surface markers CD3, CD56 and CD69 as well as
intracellular cytokine staining for IFN-g according to the
manufactures instructions (BD Biosciences). Cells were
analyzed by flow cytometry.
Proliferation of allogeneic T lymphocytes
CFSE-labeled PBMCs from HCs were cultured in DC
m e d i u mw i t ha l l o g e n e i cD C su s i n gP B M C sa n dD C sa t
a 10:1 ratio. Following six days of coculture, recovered
lymphocytes were analyzed by flow cytometry. The pro-
liferation index was determined by assessment of CD4
positive and negative proliferating cells. PHA (Sigma-
Aldrich, Deisenhofen, Germany) and CMV peptide pool
65 (Peptivator, Miltenyi Biotech) served as positive con-
trols, CFSE-labeled PBMCs without DC stimulation as a
negative control. Stimulation index (SI) was determined
assessing the response to DC stimulation divided by
PHA-response (3 μg/mL).
Induction of antigen-specific T cell responses using
HLA-A*02-restricted synthetic peptides
Cytotoxic T lymphocytes (CTLs) were induced using
HLA-A*02
+ autologous peptide-pulsed 3-day DCs for spe-
cific stimulation. In brief, after generation with cocktail
RP, DCs were irradiated (35 Gy) and pulsed with 30 μM
of the synthetic peptide CMVpp65495-503 (NLVPMVATV)
or WT-1126-134 (RMFPNAPYL) for 2 h at 37°C and 5%
CO2 in a humified atmosphere. CD8
+ T cells were posi-
tively enriched from PBMCs using CD8 microbeads and
LS columns, as described by the manufacturer (Miltenyi
Biotec), and primed with 1 × 10
6 DCs in RPMI 1640 con-
taining 10% human serum, 4 mM L-glutamine, 12.5 mM
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cin (Invitrogen, Carlbad, CA) - further named CTL med-
ium. Cytokines were added as follows: IL-2 (50 IU/mL),
IL-7 (5 ng/mL, R&D Systems) and IL-15 (10 ng/mL,
ImmunoTools, Friesoythe, Germany). After 10 days of cul-
ture, CTLs were restimulated with 1 × 10
7 irradiated pep-
tide-pulsed autologous PBMCs. Cells were harvested on
day 5 after the 2
nd restimulation and stained with multi-
mer. In brief, cells were washed in PBS and stained with
multimer for 30 min at 37°C and 5% CO2 in a humified
atmosphere. After washing CD3-APC and CD8-FITC
mAb staining was performed for 10 min at 4°C. Cells were
fixed with 1% paraformaldehyde and analyzed on a FACS
Calibur within 48 h. Unspecific staining with HIV-specific
multimer was included.
ELISPOT assays
ELISPOT plates were coated overnight with unlabelled
IFN-g capture antibody in sterile PBS according to the
manufacturer’s instruction (BD ELISPOT Set). The plates
were blocked for 1 h with sterile PBS containing 1% BSA
(Miltenyi) and washed three times with sterile PBS. Single-
cell suspensions were plated in RPMI1640 (PAN) with
10% HS and plates were cultured at 37°C with 5% CO2 for
24 h, with or without peptide (30 μM). After thorough
washing, biotinylated detection antibody was added for
overnight incubation. The plates were then washed four
times in PBS/BSA containing 0.025% Tween 20. As a ter-
tiary reagent, streptavidin-HRP was added at a 1/1000
dilution in PBS/BSA/Tween 20 and incubated for 2 h, fol-
lowed by three washes with PBS containing 0.025% Tween
20 and three washes with PBS. The plates were then devel-
oped for 3-15 min using AEC substrate. The resulting
spots were counted on an AID ELISPOT Reader System
specifically designed for morphometric ELISPOT analysis.
All results were normalized to 10
6 cells and spot number
of nonstimulated cells substracted from spot number of
stimulated and nonstimulated cells was assessed.
Statistical analysis
Differences between groups were assessed using a two-
sided paired Student’s t test. A p value < 0.05 was consid-
ered statistically significant.
Results
DCs can be efficiently generated from AML patients in
CR within 3 days using a TLR-containing maturation
protocol
Monocytes were obtained by plastic adherence of
PBMCs from AML patients in CR and HCs and differ-
entiated into immature DCs using GM-CSF and IL-4
in a fast protocol lasting 48 h [26]. DC maturation was
induced after 48 h using four different cocktails sum-
marized in Table 2. Cocktail RP had been used pre-
viously to prepare 7 d DCs [27]. After a total culture
period of 72 h, cell yields of DCs based on total num-
bers of seeded cells were analyzed. Recoveries ranged
from 8.0 to 10.3%. No significant differences in recov-
ery rates were observed between patients and healthy
controls, irrespective of the maturation cocktail used
(Table 3).
TLR-containing cocktails induced a mature and stable
surface marker profile on DCs
DC populations were analyzed by flow cytometry for
expression of characteristic surface markers. In addition to
determining the percentages of positive cells compared to
isotype control, the mean fluorescence intensity (MFI) was
analyzed. A representative patient sample generated with
cocktail RP is shown in Figure 1A. Overall, DCs expressed
a mature phenotype characterized by high expression of
CD83, HLA-DR and low expression of CD14. DCs of
patients and HC expressed high levels of CD80, CD86,
CD40 and to a lesser degree the inhibitory molecule
CD274 and CD273. Statistical analysis did not reveal any
significant differences in surface molecule expression of
DCs generated with the four different cocktails. Impor-
tantly, no substantial differences with respect to surface
expression on DCs could be observed between HCs and
AML patients except for a slight trend to decreased MFIs
of the costimulatory molecules CD80 and CD86 in AML
patients. Table 4 summarizes the phenotypic analyses of
primary DCs prepared in n ≥ 6 independent experiments
from different AML patients in CR in comparison to HCs.
The stability of DC phenotype was underlined by re-plat-
ing the DCs without any cytokine support for further 24 h.
Expression data for the four costimulatory markers
Table 3 Comparison of recovery rates of primary DCs following maturation with different cocktails
Cocktail C CP R RP
Recovery
(% PBMC)
HC-DC
mean ± SD
n=
10.3 ± 6.0
8
8.0 ± 5.6
13
8.1 ± 2.9
7
8.4 ± 6.5
12
AML-DC
mean ± SD
n=
9.9 ± 5.4
14
8.5 ± 6.8
21
9.9 ± 6.3
13
9.1 ± 5.9
16
HC-DC: number of independently generated DC from healthy donors as controls.
AML-DC: number of independently generated DC from AML patients.
mean: mean, given as percentage of cells determined as quotient of recovered to seeded cells.
SD: standard deviation.
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test are presented in Table 5. No significant changes in
DC phenotype for these or any of the other measured anti-
gens (CD14, CD40, CD83, CCR7, HLA-DR) were
observed.
DCs from AML patients and HCs displayed a prominent
costimulatory profile
TLR signaling increased the functional potential of DCs
for priming T cells, but coinduction of potentially negative
immunoregulatory capacities may impair effector T cell
generation. Therefore, we examined the expression of the
following members of the B7 family: CD80 (B7.1), CD86
(B7-2), CD273 (B7-DC/PD-L2) and CD274 (B7-H1/PD-
L1). A dominance of CD80 and CD86 compared to
CD273 and CD274 was observed. Figure 1B shows MFI
values for DCs matured with cocktails R, RP, C, and CP.
All generated DCs express a positive ratio of the positive
costimulatory molecules CD80 and CD86 to the negative
costimulatory molecules CD273 and CD274. No
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Figure 1 Costimulatory profile of mature DCs generated with a 3-day protocol. (A) Shown is the expression of specific surface molecules
detected on DCs by flow cytometry in a representative patient sample generated with cocktail RP. (B) Comparison of the expression intensity of the
costimulatory molecules CD80 and CD86 and the coinhibitory molecules CD273 and CD274 between HCs and AML patients. The mean fluorescence
(MFI) of at least three individual experiments of HC and AML patients were compared using the different maturation cocktails C, CP, R, and RP.
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cules were observed using the four different maturation
cocktails (sample size: CD80/CD86/CD273/CD274 in HC:
C: n = 10/10/4/8, CP: n = 16/16/3/7, R: n = 13/11/4/13,
RP: n = 11/9/3/10; in AML patients: C: n = 10/10/4/9, CP:
n = 14/14/3/10, R: n = 10/7/4/10, RP: n = 8/6/3/6). More
importantly, we did not observe a significant difference in
costimulatory expression pattern between DCs generated
from HC and AML patients.
IL-12(p70) and IL-10 secretion by DCs
In contrast to the maturation cocktails used for genera-
tion of DCs in clinical trials so far, our primary goal was
the identification of a TLR-containing maturation cock-
tail that generates DCs in AML patients that secrete high
amounts of bioactive IL-12(p70) while producing no or
only low levels of IL-10. To investigate whether DCs
retain this capacity upon encounter with T cells in lymph
nodes, a signal 3 assay was performed. DCs were cocul-
tured with a murine fibroblast cell line that expresses
human CD40L and thereby mimics the encounter of DCs
with CD40L
+ expressing T cells. IL-12(p70) and IL-10
release was determined after coculture for 24 h by stan-
dard ELISA for a varying number of patients and HC due
to different amounts of available blood and PBMC recov-
ery (HCs: C: n = 7, CP: n = 17, R: n = 4, RP: n = 12;
Table 4 Expression of typical DC surface markers
CD14 CD40 CD80 CD83
% positive cells HD AML HD AML HD AML HD AML
C 1 ± 1 0 ± 0 100 ± 0 99 ± 1 100 ± 0 98 ± 3 100 ± 0 100 ± 0
C P 3± 42± 49 9 ± 1 9 7 ± 99 9 ± 19 8 ± 49 7 ± 99 5 ± 1 0
R 0 ± 0 1 ± 1 100 ± 0 90 ± 15 100 ± 0 100 ± 0 100 ± 0 100 ± 0
RP 8 ± 9 1 ± 0 99 ± 2 90 ± 10 99 ± 2 100 ± 0 100 ± 1 100 ± 1
MFIs
C 2 ± 1 1 ± 1 22 ± 2 27 ± 1 108 ± 2 61 ± 4 41 ± 2 35 ± 2
C P 2± 12± 11 9 ± 1 1 5 ± 28 7 ± 25 5 ± 23 6 ± 22 7 ± 2
R 2 ± 1 2 ± 1 22 ± 2 12 ± 2 129 ± 1 73 ± 2 60 ± 1 39 ± 1
R P 3± 22± 13 3 ± 2 1 3 ± 29 8 ± 28 0 ± 24 3 ± 25 2 ± 1
CD86 CD274 CCR7 HLA-DR
% positive cells HD AML HD AML HD AML HD AML
C 100 ± 0 94 ± 14 79 ± 44 78 ± 40 66 ± 37 71 ± 22 100 ± 0 100 ± 0
CP 100 ± 1 90 ± 25 99 ± 2 97 ± 5 76 ± 25 81 ± 14 100 ± 0 99 ± 2
R 100 ± 0 100 ± 0 84 ± 16 98 ± 3 66 ± 35 80 ± 13 89 ± 16 100 ± 0
RP 99 ± 1 100 ± 0 89 ± 11 99 ± 2 65 ± 33 73 ± 20 99 ± 1 100 ± 0
MFIs
C 87 ± 2 46 ± 5 10 ± 4 8 ± 3 5 ± 3 6 ± 2 278 ± 1 327 ± 1
CP 80 ± 2 49 ± 4 24 ± 1 17 ± 2 8 ± 3 18 ± 4 273 ± 1 171 ± 2
R 136 ± 1 96 ± 2 14 ± 2 23 ± 4 6 ± 2 7 ± 2 209 ± 2 223 ± 2
RP 92 ± 2 71 ± 3 12 ± 2 17 ± 1 6 ± 3 9 ± 2 540 ± 1 215 ± 2
Table 5 Expression of DC surface markers after 24 h
without any cytokines (wash-out test)
CD80 CD86
% positive cells 0 h 24 h 0 h 24 h
C 100 ± 1 99 ± 1 100 ± 0 100 ± 0
CP 99 ± 1 99 ± 1 100 ± 1 100 ± 0
R 100 ± 1 99 ± 1 100 ± 1 100 ± 0
RP 99 ± 2 96 ± 4 99 ± 1 99 ± 0
MFIs
C 7 0± 2 6 9 ±2 9 3±21 2 1 ± 1
CP 76 ± 2 67 ± 2 84 ± 2 119 ± 1
R 70 ± 2 62 ± 1 112 ± 2 91 ± 2
RP 72 ± 2 46 ± 2 108 ± 2 108 ± 1
CD273 CD274
% positive cells 0 h 24 h 0 h 24 h
C 3 ± 3 11 ± 7 98 ± 2 92 ± 6
C P 4± 3 1 0 ± 89 8 ± 19 3 ± 5
R 5 ± 4 7 ± 9 93 ± 10 86 ± 9
RP 5 ± 5 15 ± 14 91 ± 10 89 ± 8
MFIs
C 1± 2 1 ± 11 1 ± 31 0 ± 1
CP 1 ± 1 1 ± 1 18 ± 2 10 ± 1
R 1 ±1 1 ± 2 1 3 ± 2 8 ±2
RP 1 ± 1 1 ± 2 13 ± 2 10 ± 1
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Page 7 of 14AML: C: n = 5, CP: n = 11, R: n = 9, RP: n = 12). The
results are shown in Figure 2 as mean values of IL-12
(p70) and IL-10 in picograms per milliliter. Unstimulated
D C sf r o mH Ca sw e l la sA M Lp a t i e n t sd i dn o ts e c r e t e
any relevant amounts of IL-12(p70) or IL-10 (< 15 pg/
mL). Because IL-10 counteracts IL-12(p70), we calculated
the ratio of IL-12(p70)/IL-10 for all DC populations: HC:
C: 6.1 ± 33.5 CP: 2.3 ± 16.4; R: 126.8 ± 2.5 and RP: 28.4 ±
6.7; AML patients: C: 16.7 ± 4.6; CP: 0.5 ± 10.3; R: 12.5 ±
25.5 and RP: 7.8 ± 17.6. Inter-individual variations were
noted in the capacity of DCs derived from different
donors to produce these cytokines, but no significant dif-
ferences between AML patients and HCs. To validate the
significance of the signal 3 assay using human CD40 L
transfected fibroblasts, we cocultured mature DCs with
autologous and allogeneic T cells for 24 h. For HC and
AML patients we observed a consistent secretion of IL-
12(p70) and no detectable level of IL-10 using the four
different cocktails. As expected, we measured higher
amounts of IL-12 in the supernatant media of DC cocul-
ture with allogeneic T cells versus autologous T cells
(data not shown).
DCs showed chemotaxis to CCL19 signals
For the successful induction of immune responses, in vivo
homing of DCs to secondary lymphoid organs is crucial.
CCR7-mediated signals control this migration process and
subsequently their positioning within defined functional
compartments. To address the migratory capacity of DCs
from AML patients, we conducted a standard trans-well
migration assay in the presence of the CCR7 ligand C-C-
motif chemokine 19 (CCL19). As illustrated in Figure 3,
DCs generated with all four cocktails showed very little
spontaneous migration in the absence of chemokines. DCs
from HCs and AML patients migrated efficiently towards
CCL19. The data suggests that DCs from AML patients
had comparable migration capacity towards chemokines
important for homing to secondary lymphoid organs com-
pared to healthy donors.
DCs prepared using TLR7/8 agonists strongly activate NK
cells
The functional interaction of DCs and NK cells plays a
crucial role in regulating the link between innate and
adaptive immune responses. The maturation process of
DCs is accompanied by a progressive accumulation of a
variety of cytokines, including IL-12(p70), which induces
NK cell activation [28]. We addressed the stimulating
capacity of DCs matured with different TLR-containing
cocktails by examining the upregulation of the activation
marker CD69 (Figure 4A/B) and the production of intra-
cellular IFN-g (Figure 4A/C) upon coculture with autolo-
gous and allogeneic NK cells. DCs were able to activate
NK cells after 24 h of coculture in an autologous as well
as in an allogeneic setting. A representative example is
shown in Figure 4A using CD69 upregulation on CD3
-/
CD56
+ NK cells as well as production of IFN-g as a read-
out. A summary of the results is shown in Figure 4B
demonstrating potent activation of autologous and allo-
geneic NK cells by DCs from HC and AML patients
using the four different cocktails (sample size for HC
allo: C/CP/R/RP n = 6/8/9/6; HC auto n = 4/4/6/6; AML
allo: n = 9/10/13/10; AML auto: n = 4/4/7/6. These
results were supported by similar findings after coculture
of DCs with isolated NK cells (negatively selected).
Again, using a purified NK cell population we were able
to detect high amounts of IFN-g in the supernatant after
24 h coculture. We did not see any significant differences
between HC and AML patients using the four different
cocktails. As the process of negative selection of NK cells
requires higher numbers of leukocytes at the beginning,
this experimental setting waso n l yd o n eu s i n gh e a l t h y
donors as the source of NK cells, hence only in an allo-
geneic setting (Figure 4C).
DCs prepared using TLR7/8 agonists stimulate allogeneic
CD4 T cells
CFSE-labeled PBMCs from HCs were cultured with allo-
geneic DCs from HC and AML patients at a 10:1 ratio.
Following six days of coculture, recovered lymphocytes
were analyzed by flow cytometry. PHA served as a posi-
tive control, CFSE-labeled PBMCs without DC stimula-
tion as a negative control. Stimulation index (SI) was
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Figure 2 Cytokine secretion assessed by signal-3 assay.C D 4 0 L -
transfected mouse fibroblasts were used as stimulators for DCs
mimicking T cell contact. Supernatants were collected after 24 h of
coculture. Cytokines were measured by standard ELISA. Independent
experiments were performed with a number of n = 4-12 donors for
C, CP, R, and RP in HCs and AML patients.
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Page 8 of 14determined by assessing the response to DC stimulation
divided by PHA-response (Figure 5A/B). We could
o b s e r v ee x c e l l e n ts t i m u l a t o r yc a p a c i t yo fa l l o g e n e i cT
cells by DCs generated from AML patients with no sig-
nificant difference between the four different maturation
cocktails. Importantly, no significant difference between
AML patients and HCs could be observed (n = HC (C/
CP/R/RP): 3/9/5/9; AML (C/CP/R/RP): 3/5/8/8).
Generation of CMVpp65- and WT-1-specific CTLs using
3-day DCs
CMVpp65- and WT-1-specific T cells were generated by
stimulation with CMVpp65495-503 (NLVPMVATV) and
WT-1126-134 (RMFPNAPYL) in vitro using peptide-
pulsed 3-day DCs with cocktail RP. After two restimula-
tions with peptide-pulsed PBMCs, antigen-specific T
cells were quantified using multimer technology. A sig-
nificant expansion of CMVpp65-specific T cells (19.8%
of total CD8 T cells) and WT-1-specific T cells (12.9%)
could be detected. (Figure 6A). To investigate the func-
tional specificity of T cell lines, ELISPOT for IFN-g
secretion was performed. Peptide-specific IFN-g secre-
tion corresponding to multimer-positive peptide-specific
T cells was observed (Figure 6B).
Discussion
DC-based vaccination has been intensively investigated
since the first trial in patients with B cell lymphoma in
1996 [29]. Although DC-based immunotherapies have
induced immunologic responses in the majority of trials,
thus far only a limited number of clinical responses
have been observed. It remains unclear why some
patients respond to DC-based immunotherapy and
others do not, but it has been suggested that the current
protocols used to generate mature DCs may not result
in optimal TH1 and NK cell responses. Also, these trials
were mainly performed in late-stage immunosuppressed
cancer patients as a result of extensive radiation, che-
motherapy and/or large tumor burdens [30]. The unique
capacity of DCs to activate and expand different arms of
cell-mediated resistance, such as NK, NKT, B and T
cells, each of which recognizes different alterations in
cancer cells, could be ideally exploited using IL-12(p70)
secreting DCs with a positive costimulatory profile.
We therefore, evaluated the generation of such DCs
from monocytes of AML patients in complete remission
following intensive chemotherapy. As a prerequisite,
monocyte counts of AML patients were analyzed before
consolidation and maintenance therapy. The mean num-
ber of leukocytes and monocytes was comparable to
HCs, making the generation of mature DCs feasible
from these patients.
The discovery that adjuvants can stimulate innate
immunity by interacting with specialized pattern recog-
nition receptors (PRRs), including TLRs, opened the
door for the inclusion of the respective agonists in DC
maturation cocktails [31]. TLRs allow the recognition of
a range of pathogens and lead to de novo transcription
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Page 9 of 14and secretion of cytokines and chemokines, enhanced
antigen presentation capacity, and superior migration to
lymphoid tissues. In humans, expression of TLR1 to 6
and TLR 8 were described in monocyte-derived DCs
[32-35]. The signaling pathways associated with ligation
of each of these TLRs are not identical; therefore dis-
tinct biologic responses are initiated upon receptor liga-
tion [36]. The availability of different synthetic ligands
for TLRs, like imiquimod (R837), resiquimod (R848),
S-27609, CL097, CL075 (3M-002), CL087, or loxoribine,
has stimulated research to use TLR agonists in matura-
tion cocktails. For example, combinations of the TLR3
ligand polyinosinic-polycytidylic acid (poly(I:C)) and the
TLR7/8 ligands R848 or CL075, supplemented with
PGE2,y i e l d e dD C sw i t hb o t hh i g hm i g r a t o r yc a p a c i t y
and high IL-12(p70) production upon T cell encounter
[37,38]. TLR-mediated maturation of ex vivo-generated
human DCs may thus be used to improve immunologic
and clinical responses in DC vaccination of cancer
patients. Furthermore, it was shown that 3-day DCs
were as effective as conventional 7-day DCs in stimulat-
ing primary, antigen-specific TH1i m m u n er e s p o n s e s .
This fast generation not only reduces labor, cost and
time required for DC development, but also represents a
model more closely resembling DC differentiation from
monocytes in vivo [26].
We tested two different TLR7/8 agonists, with or with-
out the TLR3 agonist poly(I:C), for their potency to
induce mature DCs in AML patients in comparison to
HCs. Phenotypically, DCs from AML patients showed
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-/CD56
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cells (upper panel) and DCs + allogeneic NK cells (lower panel) of one AML patient are shown (cocktail R was used for DC maturation). The dot
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percentage of CD69 expression on CD3
-/CD56
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Page 10 of 14high CD83, low CD14 and a slightly reduced expression
of the costimulatory molecules CD80 and CD86 in com-
bination with a similar expression intensity of CD274
and CD273. The predominance of positive costimulatory
molecules over inhibitory molecules translates into
potent T cell stimulation, as demonstrated by Selenko-
Gebauer et al. [39]. In accordance, we also observed a
potent allostimulatory capacity of TLR-matured DCs
from AML patients as well as healthy controls.
Successful anticancer immunotherapy requires strong
TH1 - p o l a r i z i n gi m m u n er e s p o n s e sa sw e l la sN Kc e l l
responses [40-43]. In a recently published clinical phase I
trial using RNA-transfected DCs from AML patients, a
significant correlation could be seen between clinical
responses and the induction of high numbers of activated
NK cells [9]. Thus, DCs are required that not only
express positive costimulatory markers, but also secrete
high amounts of bioactive IL-12(p70). This DC-derived
cytokine constitutes signal 3 of T cell activation and
determines outcomes of T cell differentiation as well as
NK cell activation [40,41,44]. Previous reports on DC
generation from monocytes of AML patients in remission
have used the classical cytokine cocktail containing TNF-
a,I L - 1 b, IL-6 and PGE2 for DC maturation [12,45]. This
protocol generates immature DCs over 5-7 days before
the maturation cocktail is added for the final 48 hours.
As previously described by others, DCs generated by this
cocktail do not produce measurable IL-12(p70) [27,37].
In the published literature on DC generation from AML
patients there is no data regarding secretion of DC-
derived cytokines nor is there information regarding DC
activation of NK cells [45,46]. This report is the first to
show that a TLR- containing maturation cocktail is able
to generate DCs from AML patients in only 3 days with
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Page 11 of 14high potential for induction of both T- and NK-cell
responses. We demonstrated high secretion of DC
derived IL-12(p70) which translated into strong NK cell
activation, as shown by CD69 upregulation and IFN-g
secretion by the CD3
-/CD56
+ NK cell subpopulation.
The strong effects on DC phenotype and function were
primarily induced by TLR 7/8 ligation as the addition of
the TLR3 ligand poly(I:C) did not result in any significant
changes in the expression pattern of costimulatory mole-
cules or IL-12(p70) secretion. This finding may be
explained by the low poly(I:C) concentration used in our
cocktails which is up > 100 fold lower compared to other
published reports [47,48]. The significant lower concen-
tration of poly(I:C) was chosen due to the observations
that poly(I:C) at a high concentration prevents DCs from
being able to express protein after loading with exoge-
neous RNA, while the lower concentration is still suffi-
cient for DC activation [27]. This is of utmost
importance for our planned clinical phase I/II trial, as we
will use RNA-transfected DCs for active immunotherapy
in AML patients.
A promising target antigen for immunotherapeutic
approaches in AML is WT-1, which is generally overex-
pressed in the majority of AML cases [49]. Several clini-
cal trials using active immunotherapeutic strategies have
targeted WT-1, so far with promising immunological
and clinical responses [8,50]. We tested our DCs for
their potential to expand WT-1-specific, CD8
+ T cells.
Comparative data was obtained against the immunodo-
minant CMVpp65 protein and T cell responses were
analyzed by multimer and ELISPOT for IFN-g. Equally
effective expansion of WT-1 - and CMVpp65- specific
T cells could be observed. Our data demonstrate that
TLR-containing maturation cocktail can generate DCs
from AML patients with phenotypic and functional
characteristics that are highly desirable for use in a clini-
cal trial setting.
A clinical phase I/II study is currently in preparation
using non-leukemic monocytes for generation of autolo-
gous DCs in AML patients in complete remission. These
DCs will be transfected with RNA encoding leukemia-
associated antigens for induction of leukemia-specific
immune responses in vaccinated patients. Through their
secretion of IL-12(p70), the DCs will favour type 1 polari-
zation of T cells while allowing NK cell activation to be
initiated at the same time. We believe that these DCs are
highly suitable for application in cancer immunotherapy.
Conclusions
To our knowledge, this is the first report in which a TLR-
containing maturation cocktail has been used for genera-
tion of young, 3-day, DCs from AML patients in remission
in comparison to HC. We found that mature DCs pre-
pared with the TLR7/8 agonists, R848 or CL075, displayed
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Page 12 of 14phenotypes and functions suitable for antitumor vaccine
development with no significant differences between AML
and HCs and among the different TLR-containing cock-
tails. As the manufacturing protocol is easily adaptable to
GMP requirements, we propose the implementation of
our protocol in a clinical vaccination trial in AML patients
in complete remission for eradication of minimal residual
disease.
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